Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewML 210 is a glutathione peroxidase (GPX4) inhibitor. Kills mutant RAS-expressing cell lines (IC50 values are 71 and 272 nM for HRAS G12v mutant expressing cell lines BJeLR and BJeH-LT, respectively). Exhibits 4-fold selectivity for HRAS mutant-expressing cell lines. Induces ferroptosis in tumor initiation "persister" cells and drug-resistant tumor cells.
ML 210 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 475.32 |
公式 | C22H20Cl2N4O4 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1360705-96-9 |
PubChem ID | 49766530 |
InChI Key | VIBHJPDPEVVDTB-UHFFFAOYSA-N |
Smiles | CC1=C([N+]([O-])=O)C(C(N2CCN(C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)CC2)=O)=NO1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 23.77 | 50 |
以下数据基于产品分子量 475.32。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.5 mM | 4.21 mL | 21.04 mL | 42.08 mL |
2.5 mM | 0.84 mL | 4.21 mL | 8.42 mL |
5 mM | 0.42 mL | 2.1 mL | 4.21 mL |
25 mM | 0.08 mL | 0.42 mL | 0.84 mL |
参考文献是支持产品生物活性的出版物。
Weïwer et al (2012) Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg.Med.Chem.Lett. 22 1822 PMID: 22297109
Yang et al (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156 317 PMID: 24439385
Hangauer et al (2017) Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551 247 PMID: 29088702
If you know of a relevant reference for ML 210, please let us know.
关键词: ML 210, ML 210 supplier, ML210, Glutathione, peroxidases, GPX4, inhibitors, inhibits, synthetically, lethal, compounds, mutant, RAS, HRAS, ferroptosis, tumor, initiation, cells, persister, drug, resistant, TICs, Ras, GTPases, Ferroptosis, Cancer, Stem, Cells, 6429, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 ML 210 的部分引用包括:
Jeff et al (2020) Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife 9 PMID: 32686647
您是否知道使用了 Tocris ML 210 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review ML 210 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
Written by Kirsten L. Bryant, Adrienne D. Cox and Channing J. Der, this review provides a comprehensive overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutic vulnerabilities are explored. This review also includes a detailed section on RAS drug discovery and targeting synthetic lethal interactors of mutant RAS. Compounds available from Tocris are listed.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.